跳转至内容
Merck

Y0001556

Ciclesonide impurity C

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价


About This Item

分類程式碼代碼:
41116107
NACRES:
NA.24

生物源

synthetic

等級

pharmaceutical primary standard

agency

EP

API 家族

ciclesonide

形狀

powder

包裝

pkg of 10 mg

製造商/商標名

EDQM

儲存條件

protect from light

溶解度

water: <0.1 g/L

應用

pharmaceutical (small molecule)

格式

neat

運輸包裝

ambient

儲存溫度

2-8°C

一般說明

Ciclesonide impurity C is an impurity of ciclesonide, which is a new-generation, non-halogenated glucocorticoid.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Ciclesonide impurity C is used as a EP reference standard to quantify the analyte in pharmaceutical formulations using liquid chromatography (LC) technique.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ciclesonide
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 10.3 (2017)
Ruediger Nave et al.
Clinical pharmacokinetics, 43(7), 479-486 (2004-05-14)
Ciclesonide is a novel inhaled corticosteroid developed for the treatment of asthma. To investigate the extent of oral absorption and bioavailability of ciclesonide referenced to an intravenous infusion. This information provides an estimate for the contribution of the swallowed fraction
New Drugs for Asthma, Allergy and COPD (2001)
Rethinking Cleaning Validation for API Manufacturing
Zhang C, et al.
Pharmaceutical Technology, 42, 42-54 (2018)
Pharmacokinetics of [14 C] ciclesonide after oral and intravenous administration to healthy subjects
Nave R, et al.
Clinical Pharmacokinetics, 43, 479-486 (2004)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门